

4731-33-01

**Definitions.**

(A) "Office-based opioid treatment" or "OBOT" means pharmacotherapy in a private office or public sector clinic that is not otherwise regulated by practitioners authorized to prescribe outpatient supplies of medications approved by the United States food and drug administration for the treatment of opioid use disorder. OBOT includes treatment with all controlled substance medications approved by the United States food and drug administration for such treatment. OBOT does not include treatment that occurs in the following settings:

(1) A state or local correctional facility, as defined in section 5163.45 of the Revised Code;

(2) A hospital, as defined in section 3727.01 of the Revised Code;

(3) A provider certified to provide residential and inpatient substance use disorder services, including withdrawal management, by the Ohio department of mental health and addiction services;

(4) An opioid treatment program certified by SAMHSA and accredited by an independent SAMHSA-approved accrediting body;

(5) A youth services facility, as defined in section 103.75 of the Revised Code; and

(6) An emergency medical services agency as authorized under chapter 4729 of the Revised Code.

(B) "SAMHSA" means the United States substance abuse and mental health services administration.

(C) "Addiction specialist physician" means a physician who holds one of the following medical subspecialty certifications:

(1) Subspecialty board certification in addiction medicine by the American board of preventative medicine ("ABPM");

(2) Subspecialty board certification in addiction psychiatry by the American board of psychiatry and neurology ("ABPN");

(3) Subspecialty board certification in addiction medicine by the American osteopathic association ("AOA"); or

(4) Certification by the American board of addiction medicine ("ABAM")

- (D) "Medications for Opioid Use Disorder" or "MOUD" refers to all medications approved by the United States food and drug administration for the treatment of opioid use disorder.
- (E) "Substance use disorder" indicates a problematic pattern of substance use leading to clinically significant impairment or distress as determined by application of the diagnostic criteria in the "Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-Text Revision" or "DSM-5-TR."
- (F) "OARRS" means the "Ohio Automated Rx Reporting System" drug database established and maintained pursuant to section 4729.75 of the Revised Code.
- (G) For purposes of the rules in this chapter:
- (1) "Qualified behavioral healthcare provider" means the following healthcare providers practicing within the scope of the professional license:
    - (a) Addiction medicine specialist physician, or board-certified psychiatrist, licensed under Chapter 4731 of the Revised Code;
    - (b) Psychologist, as defined in division (A) of section 4732.01 of the Revised Code, licensed under Chapter 4732 of the Revised Code;
    - (c) Licensed independent chemical dependency counselor-clinical supervisor, licensed independent chemical dependency counselor, licensed chemical dependency counselor III, licensed chemical dependency counselor II, or licensed chemical dependency counselor assistant licensed under Chapter 4758 of the Revised Code;
    - (d) Professional clinical counselor, licensed professional counselor, licensed independent social worker, licensed social worker, or marriage and family therapist, licensed under Chapter 4757 of the Revised Code;
    - (e) Advanced practice registered nurse, licensed as a clinical nurse specialist under Chapter 4723 of the Revised Code, who holds certification as a psychiatric mental health clinical nurse specialist issued by the American nurses credentialing center;
    - (f) Advanced practice registered nurse, licensed as a nurse practitioner under Chapter 4723 of the Revised Code, who holds certification as a psychiatric mental health nurse practitioner issued by the American nurses credentialing center; and

- (g) An advanced practice registered nurse, licensed under Chapter 4723 of the Revised Code, who holds subspecialty certification as a certified addiction registered nurse-advanced practice issued by the addictions nursing certification board.
- (2) Nothing in this paragraph shall be construed to prohibit a physician assistant licensed under Chapter 4730 of the Revised Code who practices under a supervision agreement with a board-certified addiction psychiatrist, board certified addiction medicine specialist, or psychiatrist who is licensed as a physician under Chapter 4731 of the Revised Code, from providing services within the normal course of practice and expertise of the supervising physician, including addiction services, other mental health services, and physician delegated prescriptive services in compliance with Ohio and federal laws and rules.
- (H) "Community addiction services provider" has the same meaning as in section 5119.01 of the Revised Code.
- (I) "Community mental health services provider" has the same meaning as in section 5119.01 of the Revised Code
- (J) "Induction phase" means the phase of MOUD during which the patient is started on an FDA-approved medication for substance use disorder treatment.
- (K) "Stabilization phase" means the period of time following the induction phase, when medication doses are adjusted to target a reduction in substance use disorder symptoms.
- (L) "Maintenance phase" means the ongoing period of time when the patient's medication dose reaches a therapeutic level, allowing the patient to focus on other recovery activities.
- (M) "Withdrawal management" is a set of medical interventions aimed at managing the acute physical symptoms of intoxication and withdrawal. Withdrawal management occurs when the patient has a substance use disorder and either evidence of the characteristic withdrawal syndrome produced by withdrawal from that substance or evidence that supports the expectation that such a syndrome would develop without the provision of medical withdrawal management services. Withdrawal management alone does not constitute completed substance use disorder treatment or rehabilitation.
- (N) "Ambulatory withdrawal management" means withdrawal management delivered in a medical office, public sector clinic, or urgent care facility by a physician authorized

to prescribe outpatient supplies of drugs approved by the United States food and drug administration for the treatment of substance use disorder. Ambulatory withdrawal management is the provision of medically supervised evaluation, treatment, and referral services without extended onsite monitoring. For the purpose of rule 4731-33-02 of the Administrative Code, ambulatory withdrawal management does not include withdrawal management that occurs in the following settings:

- (1) A state or local correctional facility, as defined in section 5163.45 of the Revised Code;
- (2) In-patient treatment in a hospital, as defined in section 3727.01 of the Revised Code;
- (3) A provider certified to provide residential and inpatient substance use disorder services, including withdrawal management, by the Ohio department of mental health and addition services;
- (4) An opioid treatment program certified by SAMHSA and accredited by an independent SAMHSA-approved accrediting body;
- (5) A youth services facility, as defined in section 103.75 of the Revised Code; and
- (6) An emergency medical services agency as authorized under chapter 4729 of the Revised Code.

Replaces: 4731-33-01  
Effective: 10/31/2024  
Five Year Review (FYR) Dates: 10/31/2029

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 04/30/2019, 10/31/2020

## TO BE RESCINDED

4731-33-01           **Definitions.**

- (A) "Office-based opioid treatment" or "OBOT" means medication-assisted treatment, as that term is defined in this rule, in a private office or public sector clinic that is not otherwise regulated, by practitioners authorized to prescribe outpatient supplies of medications approved by the United States food and drug administration for the treatment of opioid addiction or dependence, prevention of relapse of opioid addiction or dependence, or both. OBOT includes treatment with all controlled substance medications approved by the United States food and drug administration for such treatment. OBOT does not include treatment that occurs in the following settings:
- (1) A state or local correctional facility, as defined in section 5163.45 of the Revised Code;
  - (2) A hospital, as defined in section 3727.01 of the Revised Code;
  - (3) A provider certified to provide residential and inpatient substance use disorder services, including withdrawal management, by the Ohio department of mental health and addiction services;
  - (4) An opioid treatment program certified by SAMHSA and accredited by an independent SAMHSA-approved accrediting body; or
  - (5) A youth services facility, as defined in section 103.75 of the Revised Code.
- (B) "SAMHSA" means the United States substance abuse and mental health services administration.
- (C) "Medication-assisted treatment" means alcohol or drug addiction services that are accompanied by medication that has been approved by the United States food and drug administration for the treatment of substance use disorder, prevention of relapse of substance use disorder, or both.
- (D) "Substance use disorder" includes misuse, dependence, and addiction to alcohol and/or legal or illegal drugs, as determined by diagnostic criteria in the "Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition" or "DSM-5."
- (E) "OARRS" means the "Ohio Automated Rx Reporting System" drug database established and maintained pursuant to section 4729.75 of the Revised Code.
- (F) For purposes of the rules in Chapter 4731-33 of the Administrative Code:

- (1) "Qualified behavioral healthcare provider" means the following who is practicing within the scope of the professional license:
  - (a) Board certified addictionologist, board certified addiction psychiatrist, or psychiatrist, licensed under Chapter 4731. of the Revised Code;
  - (b) Licensed independent chemical dependency counselor-clinical supervisor, licensed independent chemical dependency counselor, licensed chemical dependency counselor III, licensed chemical dependency counselor II, or licensed chemical dependency counselor assistant licensed under Chapter 4758. of the Revised Code;
  - (c) Professional clinical counselor, licensed professional counselor, licensed independent social worker, licensed social worker, or marriage and family therapist, licensed under Chapter 4757. of the Revised Code;
  - (d) Advanced practice registered nurse, licensed as a clinical nurse specialist under Chapter 4723. of the Revised Code, who holds certification as a psychiatric mental health clinical nurse specialist issued by the American nurses credentialing center.
  - (e) Advanced practice registered nurse, licensed as a nurse practitioner under Chapter 4723. of the Revised Code, who holds certification as a psychiatric mental health nurse practitioner issued by the American nurses credentialing center;
  - (f) Psychologist, as defined in division (A) of section 4732.01 of the Revised Code, licensed under Chapter 4732. of the Revised Code; or
  - (g) An advanced practice registered nurse, licensed under Chapter 4723. of the Revised Code, who holds subspecialty certification as a certified addiction registered nurse-advanced practice issued by the addictions nursing certification board.
- (2) Nothing in this paragraph shall be construed to prohibit a physician assistant licensed under Chapter 4730. of the Revised Code who practices under a supervision agreement with a board certified addiction psychiatrist, board certified addictionologist, or psychiatrist who is licensed as a physician under Chapter 4731. of the Revised Code, from providing services within the normal course of practice and expertise of the supervising physician, including addiction services, other mental health services, and physician delegated prescriptive services in compliance with Ohio and federal laws and rules.

- (G) "Community addiction services provider," has the same meaning as in section 5119.01 of the Revised Code.
- (H) "Community mental health services provider," has the same meaning as in section 5119.01 of the Revised Code.
- (I) "Induction phase," means the phase of opioid treatment during which maintenance medication dosage levels are adjusted until a patient attains stabilization.
- (J) "Stabilization phase," means the medical and psychosocial process of assisting the patient through acute intoxication and withdrawal management to the attainment of a medically stable, fully supported substance-free state, which may include the use of medications.
- (K) "Withdrawal management" or "detoxification" is a set of medical interventions aimed at managing the acute physical symptoms of intoxication and withdrawal. Detoxification denotes a clearing of toxins from the body of the patient who is acutely intoxicated and/or dependent on a substance of abuse. Withdrawal management seeks to minimize the physical harm caused by the intoxication and withdrawal of a substance of abuse. Withdrawal management or detoxification occurs when the patient has a substance use disorder and either evidence of the characteristic withdrawal syndrome produced by withdrawal from that substance or evidence that supports the expectation that such a syndrome would develop without the provision of detoxification services. Withdrawal management alone does not constitute substance abuse treatment or rehabilitation.
- (L) "Ambulatory detoxification" means withdrawal management delivered in a medical office, public sector clinic, or urgent care facility by a physician authorized to prescribe outpatient supplies of drugs approved by the United States food and drug administration for the treatment of addiction, prevention of relapse of addiction, or both. Ambulatory detoxification is the provision of medically supervised evaluation, withdrawal management, and referral services without extended onsite monitoring. For the purpose of rule 4731-33-02 of the Administrative Code, ambulatory detoxification does not include withdrawal management that occurs in the following settings:
- (1) A state or local correctional facility, as defined in section 5163.45 of the Revised Code;
  - (2) In-patient treatment in a hospital, as defined in section 3727.01 of the Revised Code;



- (3) A provider certified to provide residential and inpatient substance use disorder services, including withdrawal management, by the Ohio department of mental health and addition services;
- (4) An opioid treatment program certified by SAMHSA and accredited by an independent SAMHSA-approved accrediting body; or
- (5) A youth services facility, as defined in section 103.75 of the Revised Code.

Effective: 10/31/2024

Five Year Review (FYR) Dates: 7/25/2024

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056,4731.83  
Prior Effective Dates: 04/30/2019, 10/31/2020

4731-33-02**Standards and procedures for withdrawal management for substance use disorder.**

- (A) A physician who provides withdrawal management, as that term is defined in rule 4731-33-01 of the Administrative Code, shall comply with all federal and state laws and rules applicable to prescribing.
- (B) Prior to providing ambulatory withdrawal management for any substance use disorder the physician shall inform the patient that ambulatory withdrawal management alone is not complete treatment for a substance use disorder. If the patient prefers continuing treatment for a substance use disorder, the physician shall comply with the requirements of section 3719.064 of the Revised Code.
- (C) The physician shall provide accurate, objective and complete documentation of all patient encounters, including referrals, test results, and significant changes to the treatment plan.
- (D) When providing withdrawal management for opioid use disorder the physician may use a medical device that is approved by the United States food and drug administration as an aid in the reduction of opioid withdrawal symptoms.
- (E) Ambulatory withdrawal management for opioid use disorder.
- (1) The physician shall provide ambulatory withdrawal management only when the following conditions are met:
- (a) The patient has adequate social, medical, and psychiatric stability to engage in and safely complete ambulatory withdrawal management; and
- (b) There is little risk of medication diversion.
- (2) The physician shall provide ambulatory withdrawal management under a defined set of policies and procedures or medical protocols, with patient placement in outpatient or residential settings consistent with American society of addiction medicine's level of care criteria. Such services are designed to treat the patient's level of clinical severity, to achieve safe and comfortable withdrawal from a drug, and to effectively facilitate the patient's transition into treatment and recovery. In the event that ambulatory withdrawal management is unsafe or inappropriate for a patient, referral to a higher level of care, such as inpatient hospitalization shall be completed. The ASAM criteria can be obtained from the website of the American society of addiction medicine at <https://www.asam.org/>. A copy of the ASAM criteria may be reviewed at the medical board office, 30 East Broad street, third floor, Columbus, Ohio, during normal business hours.

- (3) Prior to providing ambulatory withdrawal management, the physician shall perform an assessment of the patient to gather sufficient information and data to justify the use of this treatment intervention. The assessment shall include a thorough medical history and physical examination sufficient to assure safety in commencing ambulatory withdrawal management and shall include a review of the patient's prescription history in OARRS. The assessment must focus on signs and symptoms associated with opioid use disorder and include assessment with a nationally recognized scale, such as one of the following:
- (a) "Objective Opioid Withdrawal Scale" (OOWS);
  - (b) "Clinical Opioid Withdrawal Scale" (COWS); or
  - (c) "Subjective Opioid Withdrawal Scale" (SOWS).
- (4) If any part of the assessment cannot be completed prior to the initiation of treatment, the physician shall complete as soon as possible following initiation of treatment.
- (5) The physician shall inform the patient about the following before treatment for opioid withdrawal is initiated:
- (a) The withdrawal management process and importance of subsequent treatment for substance use disorder, including information about all medications approved by the United States food and drug administration for use in MOUD treatment;
  - (b) The risk of relapse and lethal overdose following completion of withdrawal without entry into continuation of MOUD treatment;
  - (c) The safe storage and disposal of prescribed medications.
- (6) The physician shall not establish standardized regimens of medications for management of substance withdrawal symptomatology but shall formulate an individualized treatment plan based on the needs of the specific patient.
- (7) For persons projected to be involved in withdrawal management for six months or less, the physician shall offer the patient counseling as described in paragraph (D) of rule 4731-33-03 of the Administrative Code.
- (8) The physician shall require the patient to undergo urine and/or other toxicological screenings during withdrawal management in order to assess for use of licit and/or illicit drugs. The physician shall consider revising the treatment plan or

referring a patient who has a positive toxicological screening result to a higher level of care.

(9) The physician shall comply with the following requirements for the use of medication:

(a) The physician may treat the patient's withdrawal symptoms with any of the following medications as determined to be most appropriate for the patient.

(i) A medication that is specifically FDA approved for the alleviation of withdrawal symptoms. Methadone may only be utilized with strict adherence to the stipulations of 21 C.F.R. 1306.07(b).

(ii) An alpha-2 adrenergic agent along with other non-narcotic medications as recommended in the American Society of Addiction Medicine's National Practice Guideline (<https://www.asam.org/>), which is available on the Medical Board's website at: <https://www.med.ohio.gov>;

(iii) A combination of buprenorphine and low dose naloxone (buprenorphine/naloxone combination product), unless contraindicated, in which case buprenorphine mono-product may be utilized.

(b) The physician shall not use anesthetic agents to treat the patient's withdrawal symptoms.

(c) The physician shall comply with the following:

(i) Treatment with a buprenorphine product must be in compliance with the United States food and drug administration approved "Risk Evaluation and Mitigation Strategy" for buprenorphine products, which can be found on the United States food and drug administration website at the following address: <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm>.

(ii) The physician shall determine on an individualized basis the appropriate dosage of medication to ensure stabilization during withdrawal management.

(a) The dosage level shall be that which is effective in suppressing withdrawal symptoms and is well tolerated by the patient.

- (b) The dosage level shall be consistent with the currently accepted standards of care.
- (iii) In withdrawal management programs of thirty days or less duration, the physician shall not prescribe nor dispense more than one week of unsupervised or take-home medications for the patient.
- (10) The physician shall offer the patient a prescription for an overdose reversal drug, directly provide them with the overdose reversal drug, or direct the patient to an easily accessible source to obtain the overdose reversal drug, such as <http://www.naloxone.ohio.gov>, a local health department, or other agency or facility that provides overdose reversal drugs.
- (a) The physician shall ensure that the patient and, if possible, those residing with the patient receive instruction on the drug's use including, but not limited to, recognizing the signs and symptoms of opioid overdose and calling 911 in an overdose situation.
- (b) The physician shall offer the patient a new prescription for an overdose reversal drug upon expiration or use.
- (c) The physician shall be exempt from this requirement if the patient refuses the prescription. If the patient refuses the prescription the physician shall provide the patient with information on where to obtain the overdose reversal drug without a prescription.
- (11) The physician shall take steps to reduce the risk of medication diversion by doing one or more of the following: frequent office visits, pill counts, urine drug screening, and frequent checks of OARRS.
- (F) The physician who provides ambulatory withdrawal management for benzodiazepines or other sedatives shall comply with paragraphs (A), (B), and (C) of this rule and "TIP 45, A Treatment Improvement Protocol for Detoxification and Substance Abuse Treatment" by the substance abuse and mental health services administration available from the substance abuse and mental health services administration website at the following link: <https://store.samhsa.gov/> (search for "TIP 45") and available on the medical board's website at: <https://med.ohio.gov>.
- (1) The physician shall provide ambulatory withdrawal management for benzodiazepines with medication only when a patient has sufficient social, medical, and psychiatric stability when their use of benzodiazepines was primarily in therapeutic dose ranges and when they do not have polysubstance dependence. The patient should exhibit no more than mild to moderate

withdrawal symptoms, have no comorbid medical condition or severe psychiatric disorder, and no history of withdrawal seizures or withdrawal delirium.

- (2) Prior to providing ambulatory withdrawal management, the physician shall perform an assessment of the patient that focuses on signs and symptoms associated with benzodiazepine or other sedative use disorder and include assessment with a nationally recognized scale, such as the "Clinical Institute Withdrawal Assessment for Benzodiazepines" ("CIWA-B").
- (3) Prior to providing ambulatory withdrawal management, the physician shall conduct a biomedical and psychosocial evaluation of the patient to gather sufficient information and data to justify the use of this treatment intervention.
- (4) The physician shall instruct the patient about the following before treatment for benzodiazepine withdrawal management is initiated:
  - (a) Not to drive or operate dangerous machinery during treatment;
  - (b) The withdrawal management process and importance of subsequent treatment for substance use disorder, including information about all medications approved by the United States food and drug administration for use in substance use disorder treatment;
  - (c) The risk of relapse and lethal overdose following completion of withdrawal without entry into continuation of treatment for substance use disorder;  
and
  - (d) The safe storage and disposal of prescribed medications.
- (5) During the ambulatory withdrawal management, the physician shall regularly assess the patient so that medication dosage can be adjusted if needed.
  - (a) The physician shall require the patient to undergo urine and/or other toxicological screenings during withdrawal management in order to assess for the use of licit and/or illicit drugs.
  - (b) The physician shall consider revising the treatment plan or referring the patient who has a positive toxicology screening to a higher level of care.
  - (c) The physician shall take steps to reduce the risk of diversion by doing one or more of the following: frequent office visits, pill counts, urine drug screening and frequent checks of OARRS.

(G) The physician who provides ambulatory withdrawal management for withdrawal from alcohol shall comply with paragraphs (A), (B), and (C) of this rule and “Clinical Practice Guideline on Alcohol Withdrawal Management” by the American society of addiction medicine available from the American society of addiction medicine website at the following link: <https://www.asam.org/quality-care/clinical-guidelines/alcohol-withdrawal-management-guideline>.

- (1) The physician shall provide ambulatory withdrawal from alcohol only when:
  - (a) The patient has sufficient social, medical, and psychiatric stability to adhere to prescribed treatments and successfully complete withdrawal with minimal risk of complications;
  - (b) The patient is not at risk for serious withdrawal from substances other than alcohol; and
  - (c) The patient has no history of withdrawal seizures or withdrawal delirium.
- (2) Prior to providing ambulatory withdrawal management, the physician shall perform an assessment of the patient. The assessment must focus on signs and symptoms associated with alcohol use disorder and include assessment with a nationally recognized scale, such as the "Clinical Institute Withdrawal Assessment for Alcohol-revised" ("CIWA-AR").
- (3) Prior to providing ambulatory withdrawal management, the physician shall perform a biomedical and psychosocial evaluation to gather sufficient information and data to justify the use of this treatment intervention.
- (4) During the ambulatory withdrawal management, the physician shall regularly assess the patient so that the dosage can be adjusted if needed.
  - (a) The physician shall require the patient to undergo toxicological screenings in order to assess for the presence of alcohol metabolites, licit or illicit drugs;
  - (b) The physician shall consider revising the treatment plan or referring a patient who has a positive toxicological screening test to a higher level of care; and
  - (c) The physician shall take steps to reduce the risk of diversion by doing one or more of the following: frequent office visits, pill counts, urine drug screening and frequent checks of OARRS.



Replaces: 4731-33-02  
Effective: 10/31/2024  
Five Year Review (FYR) Dates: 10/31/2029

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 10/31/2020

## TO BE RESCINDED

**4731-33-02 Standards and procedures for withdrawal management for drug or alcohol addiction.**

- (A) A physician who provides withdrawal management, as that term is defined in rule 4731-33-01 of the Administrative Code, shall comply with all federal and state laws and rules applicable to prescribing, including holding a "DATA 2000" waiver to prescribe buprenorphine if buprenorphine is to be prescribed for withdrawal management in a medical office, public sector clinic, or urgent care facility.
- (B) Prior to providing ambulatory detoxification, as that term is defined in rule 4731-33-01 of the Administrative Code, for any substance use disorder the physician shall inform the patient that ambulatory detoxification alone is not substance abuse treatment. If the patient prefers substance abuse treatment, the physician shall comply with the requirements of section 3719.064 of the Revised Code, by completing all of the following actions:
- (1) Both orally and in writing, give the patient information about all drugs approved by the U.S. food and drug administration for use in medication-assisted treatment, including withdrawal management. That information was given shall be documented in the patient's medical record.
  - (2) If the patient agrees to enter opioid treatment and the physician determines that such treatment is clinically appropriate, the physician shall refer the patient to an opioid treatment program licensed or certified by the Ohio department of mental health and addiction services to provide such treatment or to a physician, physician assistant, or advanced practice registered nurse who provides treatment using Naltrexone or who holds the DATA 2000 waiver to provide office-based treatment for opioid use disorder. The name of the program, physician, physician assistant, or advanced practice registered nurse to whom the patient was referred, and the date of the referral shall be documented in the patient record.
- (C) When providing withdrawal management for opioid use disorder the physician may use a medical device that is approved by the United States food and drug administration as an aid in the reduction of opioid withdrawal symptoms.
- (D) Ambulatory detoxification for opioid addiction.
- (1) The physician shall provide ambulatory detoxification only when all of the following conditions are met:
    - (a) A positive and helpful support network is available to the patient.

- (b) The patient has a high likelihood of treatment adherence and retention in treatment.
  - (c) There is little risk of medication diversion.
- (2) The physician shall provide ambulatory detoxification under a defined set of policies and procedures or medical protocols consistent with American society of addiction medicine's level I-D or II-D level of care, under which services are designed to treat the patient's level of clinical severity, to achieve safe and comfortable withdrawal from a mood-altering drug, and to effectively facilitate the patient's transition into treatment and recovery. The ASAM criteria, third edition, can be obtained from the website of the American society of addiction medicine at <https://www.asam.org/>. A copy of the ASAM criteria may be reviewed at the medical board office, 30 East Broad street, third floor, Columbus, Ohio, during normal business hours.
- (3) Prior to providing ambulatory detoxification, the physician shall perform an assessment of the patient. The assessment shall include a thorough medical history and physical examination. The assessment must focus on signs and symptoms associated with opioid addiction and include assessment with a nationally recognized scale, such as one of the following:
  - (a) "Objective Opioid Withdrawal Scale" (OOWS);
  - (b) "Clinical Opioid Withdrawal Scale" (COWS); or
  - (c) "Subjective Opioid Withdrawal Scale" (SOWS).
- (4) Prior to providing ambulatory detoxification, the physician shall conduct a biomedical and psychosocial evaluation of the patient, to include the following:
  - (a) A comprehensive medical and psychiatric history;
  - (b) A brief mental status exam;
  - (c) Substance abuse history;
  - (d) Family history and psychosocial supports;
  - (e) Appropriate physical examination;
  - (f) Urine drug screen or oral fluid drug testing;
  - (g) Pregnancy test for women of childbearing age and ability;

- (h) Review of the patient's prescription information in OARRS;
  - (i) Testing for human immunodeficiency virus;
  - (j) Testing for hepatitis B;
  - (k) Testing for hepatitis C; and
  - (l) Consideration of screening for tuberculosis and sexually-transmitted diseases in patients with known risk factors.
  - (m) For other than toxicology tests for drugs and alcohol, appropriate history, substance abuse history, and pregnancy test, the physician may satisfy the assessment requirements by reviewing records from a physical examination and laboratory testing of the patient that was conducted within a reasonable period of time prior to the visit. If any part of the assessment cannot be completed prior to the initiation of treatment, the physician shall document the reason in the medical record.
- (5) The physician shall request and document review of an OARRS report on the patient.
- (6) The physician shall inform the patient about the following before the patient is undergoing withdrawal from opioids:
- (a) The detoxification process and potential subsequent treatment for substance use disorder, including information about all drugs approved by the United States food and drug administration for use in medication-assisted treatment;
  - (b) The risk of relapse following detoxification without entry into medication-assisted treatment;
  - (c) The high risk of overdose and death when there is a relapse following detoxification;
  - (d) The safe storage and disposal of the medications.
- (7) The physician shall not establish standardized routines or schedules of increases or decreases of medications but shall formulate a treatment plan based on the needs of the specific patient.

- (8) For persons projected to be involved in withdrawal management for six months or less, the physician shall offer the patient counseling as described in paragraphs (F) and (G) of rule 4731-33-03 of the Administrative Code.
- (9) The physician shall require the patient to undergo urine and/or other toxicological screenings during withdrawal management in order to demonstrate the absence of use of alternative licit and/or illicit drugs. The physician shall consider referring a patient who has a positive urine/and or toxicological screening to a higher level of care, with such consideration documented in the patient's medical record.
- (10) The physician shall comply with the following requirements for the use of medication:
- (a) The physician may treat the patient's withdrawal symptoms by use of any of the following drugs as determined to be most appropriate for the patient.
- (i) A drug, excluding methadone, that is specifically FDA approved for the alleviation of withdrawal symptoms.
- (ii) An alpha-2 adrenergic agent along with other non-narcotic medications as recommended in the American Society of Addiction Medicine's National Practice Guideline (<https://www.asam.org/>), which is available on the Medical Board's website at: <https://www.med.ohio.gov>;
- (iii) A combination of buprenorphine and low dose naloxone (buprenorphine/naloxone combination product). However, buprenorphine without naloxone (buprenorphine mono-product) may be used if a buprenorphine/naloxone combination product is contraindicated, with the contraindication documented in the patient record.
- (b) The physician shall not use any of the following drugs to treat the patient's withdrawal symptoms:
- (i) Methadone;
- (ii) Anesthetic agents
- (c) The physician shall comply with the following:
- (i) The physician shall not initiate treatment with buprenorphine to manage withdrawal symptoms until between twelve and eighteen

hours after the last dose of short-acting agonist such as heroin or oxycodone, and twenty-four to forty-eight hours after the last dose of long-acting agonist such as methadone. Treatment with a buprenorphine product must be in compliance with the United States food and drug administration approved "Risk Evaluation and Mitigation Strategy" for buprenorphine products, which can be found on the United States food and drug administration website at the following address: <https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm>.

(ii) The physician shall determine on an individualized basis the appropriate dosage of medication to ensure stabilization during withdrawal management.

(a) The dosage level shall be that which is well tolerated by the patient.

(b) The dosage level shall be consistent with the minimal standards of care.

(iii) In withdrawal management programs of thirty days or less duration, the physician shall not allow more than one week of unsupervised or take-home medications for the patient.

(11) The physician shall offer the patient a prescription for a naloxone kit.

(a) The physician shall ensure that the patient receives instruction on the kit's use including, but not limited to, recognizing the signs and symptoms of overdose and calling 911 in an overdose situation.

(b) The physician shall offer the patient a new prescription for naloxone upon expiration or use of the old kit.

(c) The physician shall be exempt from this requirement if the patient refuses the prescription. If the patient refuses the prescription the physician shall provide the patient with information on where to obtain a kit without a prescription.

(12) The physician shall take steps to reduce the chances of medication diversion by using the appropriate frequency of office visits, pill counts, and weekly checks of OARRS.

(E) The physician who provides ambulatory detoxification with medication management for withdrawal from benzodiazepines or other sedatives shall comply with paragraphs

(A), (B), and (C) of this rule and "TIP 45, A Treatment Improvement Protocol for Detoxification and Substance Abuse Treatment" by the substance abuse and mental health services administration available from the substance abuse and mental health services administration website at the following link: <https://store.samhsa.gov/> (search for "TIP 45") and available on the medical board's website at: <https://med.ohio.gov>.

- (1) The physician shall provide ambulatory detoxification with medication management only when a positive and helpful support network is available to the patient whose use of benzodiazepines was mainly in therapeutic ranges and who does not have polysubstance dependence. The patient should exhibit no more than mild to moderate withdrawal symptoms, have no comorbid medical condition or severe psychiatric disorder, and no past history of withdrawal seizures or withdrawal delirium.
- (2) Prior to providing ambulatory detoxification, the physician shall perform and document an assessment of the patient that focuses on signs and symptoms associated with benzodiazepine or other sedative use disorder and include assessment with a nationally recognized scale, such as the "Clinical Institute Withdrawal Assessment for Benzodiazepines" ("CIWA-B").
- (3) Prior to providing ambulatory detoxification, the physician shall conduct and document a biomedical and psychosocial evaluation of the patient meeting the requirements of paragraph (B)(4) of this rule.
- (4) The physician shall instruct the patient not to drive or operate dangerous machinery during treatment.
- (5) During the ambulatory detoxification, the physician shall regularly assess the patient during the course of treatment so that dosage can be adjusted if needed.
  - (a) The physician shall require the patient to undergo urine and/or other toxicological screenings during withdrawal management in order to demonstrate the absence of use of alternative licit and/or illicit drugs.
  - (b) The physician shall document consideration of referring the patient who has a positive urine and/or toxicology screening to a higher level of care.
  - (c) The physician shall take steps to reduce the chances of diversion by using the appropriate frequency of office visits, pill counts, and weekly checks of OARRS.
- (F) The physician who provides ambulatory detoxification with medication management of withdrawal from alcohol addiction shall comply with paragraphs (A), (B), and

(C) of this rule and "TIP 45, A Treatment Improvement Protocol for Detoxification and Substance Abuse Treatment" by the substance abuse and mental health services administration available from the substance abuse and mental health services administration website at the following link: <https://store.samhsa.gov/> (search for "TIP 45") and available on the medical board's website at: <https://med.ohio.gov>.

- (1) The physician shall provide ambulatory detoxification from alcohol with medication management only when a positive and helpful support network is available to the patient who does not have a polysubstance dependence. The patient should exhibit no more than mild to moderate withdrawal symptoms, have no comorbid medical conditions or severe psychiatric disorders, and no past history of withdrawal seizures or withdrawal delirium.
- (2) Prior to providing ambulatory detoxification, the physician shall perform and document an assessment of the patient. The assessment must focus on signs and symptoms associated with alcohol use disorder and include assessment with a nationally recognized scale, such as the "Clinical Institute Withdrawal Assessment for Alcohol-revised" ("CIWA-AR").
- (3) Prior to providing ambulatory detoxification, the physician shall perform and document a biomedical and psychosocial evaluation meeting the requirements of paragraph (D)(4) of this rule.
- (4) During the course of ambulatory detoxification, the physician shall assess the patient regularly:
  - (a) The physician shall adjust the dosage as medically appropriate;
  - (b) The physician shall require the patient to undergo urine and/or other toxicological screenings in order to demonstrate the absence of illicit drugs;
  - (c) The physician shall document the consideration of referring a patient who has a positive urine and/or toxicological screening to a higher level of care;
- (5) If the patient agrees to enter alcohol treatment and the physician determines that such treatment is clinically appropriate, the physician shall refer the patient to an alcohol treatment program licensed or certified by the Ohio department of mental health and addiction services to provide such treatment or to a physician, physician assistant, or advanced practice registered nurse who provides treatment using any FDA approved forms of medication assisted treatment for alcohol use disorder. The name of the program, physician,



physician assistant, or advanced practice registered nurse to whom the patient was referred, and the date of the referral shall be documented in the patient record.

- (6) The physician shall instruct the patient not to drive or operate dangerous machinery during treatment.

Effective: 10/31/2024

Five Year Review (FYR) Dates: 7/25/2024

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 10/31/2020

4731-33-03

**Office-based opioid treatment.**

(A) A physician who provides office-based opioid treatment ("OBOT") shall comply with the following requirements:

- (1) Before initiating OBOT, the physician shall comply with section 3719.064 of the Revised Code:
- (2) Comply with all federal and state laws and regulations governing the prescribing of the medication:
- (3) Complete at least eight hours of "Category 1" continuing medical education relating to substance use disorder and addiction every two years. Courses completed in compliance with this requirement shall be accepted toward meeting the physician's "Category 1" continuing medical education requirement for biennial renewal of the physician's license:
- (4) The physician who provides OBOT shall perform an assessment of the patient to gather sufficient information and data to justify the use of this treatment intervention. The assessment shall include a thorough medical history, examination and laboratory testing. If any part of the assessment cannot be completed prior to the initiation of OBOT, the physician shall complete as soon as possible following initiation of treatment; and
- (5) The physician shall provide accurate, objective and complete documentation of all patient encounters, including referrals, test results, and significant changes to the treatment plan.

(B) The physician who provides OBOT shall establish a treatment plan that includes the following:

- (1) The physician's rationale for selection of the specific drug to be used in the treatment based upon discussion of all MOUDs and non-medication options with the patient:
- (2) Patient education:
- (3) Random urine-drug screens;
- (4) A signed treatment agreement that outlines the responsibilities of the patient and the physician, and documents the patient's consent for treatment;
- (5) Documentation regarding psychosocial interventions, pursuant to paragraph (D) of this rule; and

(6) The treatment plan shall be revised if the patient does not show improvement with the original plan.

(C) The physician shall provide OBOT in accordance with an acceptable treatment protocol for assessment, induction, stabilization, maintenance, and tapering. Acceptable protocols are any of the following:

(1) TIP 63 "Medications for Opioid Use Disorder" (2021) available from the <https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP21-02-01-002>.

(2) "ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update" available from the website of the American society of addiction medicine at <https://www.asam.org/quality-care/clinical-guidelines/national-practice-guideline>.

(D) The physician shall do the following with respect to psychosocial treatment for patients receiving OBOT:

(1) Assess for psychosocial treatment needs in addition to medication;

(2) Offer psychosocial interventions or referrals for psychosocial interventions to all patients, but OBOT should not be declined or discontinued if the patient is unable or unwilling to engage in psychosocial interventions;

(3) Ensure that psychosocial interventions are person-centered and tailored to the patient's insight, motivation, and stage of recovery;

(4) Focus the psychosocial interventions on retaining the patient in treatment, stabilizing the patient and assisting with progress in the patient's treatment and recovery;

(5) If the psychosocial interventions are not available or if the patient declines to participate, the physician shall continue to treat the patient with OBOT provided that the patient adheres to all other treatment requirements;

(6) Psychosocial treatment or intervention includes the following:

(a) Cognitive behavioral treatment;

(b) Community reinforcement approach;

(c) Contingency management and motivational incentives;

- (d) Motivational interviewing;
    - (e) Behavioral couples counseling;
    - (f) Twelve-step facilitation; and
    - (g) Other therapies based on the patient's individual needs;
  - (7) When necessary, the physician may make referrals for psychosocial treatment to qualified behavioral healthcare providers, community addiction services or community mental health services providers as defined in rule 4731-33-01 of the Administrative Code; and
  - (8) The physician may also refer patients for treatment with non-licensed paraprofessionals such as case managers and peer support specialists if the physician determines such intervention would benefit the patient.
- (E) The physician who provides OBOT shall offer the patient a prescription for an overdose reversal drug, directly provide the patient with the overdose reversal drug, or direct the patient to an easily accessible source to obtain overdose reversal drugs, such as <http://www.naloxone.ohio.gov>, a local health department, or other agency or facility that provides overdose reversal drugs.
- (1) The physician shall ensure that the patient and, if possible, those residing with the patient, receive instruction on the overdose reversal drug's use including, but not limited to, recognizing the signs and symptoms of opioid overdose and calling 911 in an overdose situation.
  - (2) The physician shall offer the patient a new prescription for an overdose reversal drug upon expiration or use.
  - (3) The physician shall be exempt from this requirement if the patient refuses the prescription. If the patient refuses the prescription the physician shall provide the patient with information on where to obtain overdose reversal drugs without a prescription.
- (F) In addition to paragraphs (A) to (E) of this rule, the physician who provides OBOT using buprenorphine products shall comply with the following requirements:
- (1) Treatment with a buprenorphine product must be in compliance with the United States food and drug administration approved "Risk Evaluation and Mitigation Strategy" for buprenorphine products, which can be found on the United States food and drug administration website at the following address: <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm>. With the exception of

those conditions listed in paragraph (G)(2) of this rule, a physician who treats the opioid use disorder with a buprenorphine product shall only prescribe buprenorphine/naloxone combination products for use in OBOT.

(2) The physician may prescribe buprenorphine without naloxone (buprenorphine mono-product) only in the following situation:

(a) When a patient is pregnant or breast-feeding;

(b) When converting a patient from buprenorphine mono-product to buprenorphine/naloxone combination product;

(c) In formulations other than tablet or film form for indications approved by the United States food and drug administration; or

(d) When the patient has a genuine allergy to or intolerance of a buprenorphine/naloxone combination product.

(3) Due to a higher risk of fatal overdose when buprenorphine is prescribed with other opioids, benzodiazepines, sedative hypnotics, carisoprodol, gabapentin, or tramadol, the physician shall only co-prescribe these substances when it is medically necessary.

(a) The physician shall verify the diagnosis for which the patient is receiving the other drug and coordinate care with the prescriber for the other drug, including whether acceptable alternative treatments are available and whether it is possible to lower the dose or discontinue the drug. If the physician prescribing buprenorphine is the prescriber of the other drug, the physician shall also consider these options and consider consultation with another healthcare provider. The physician shall educate the patient about the serious risks of the combined use.

(b) The physician shall document the rationale for discontinuing, lowering, or continuing the medication given potential risks and benefits.

(4) During the induction phase the physician shall not prescribe a dosage that exceeds the recommendation in the United States food and drug administration approved labeling, except for medically indicated circumstances as documented in the patient record. The physician shall see the patient at least once a week during this phase.

(5) During the maintenance phase, the physician shall prescribe a dosage of buprenorphine that avoids intoxication or sedation, prevents withdrawal, and suppresses significant drug craving. For the first twelve months of treatment,

the physician shall prescribe no more than a one-month supply of the buprenorphine product unless utilizing a formulation with duration of action exceeding one month, such as injections or implants.

- (6) The physician shall reduce the risk of buprenorphine diversion by using the lowest effective dose, and by using one or more of the following: scheduling appropriate frequency of office visits, conducting random pill counts, checking OARRS and utilizing drug testing, serum medication levels, and oral fluid testing to assess for patient adherence to prescribed buprenorphine treatment.
- (7) When using any sublingual formulation of buprenorphine, the physician shall not prescribe a dosage exceeding twenty-four milligrams of buprenorphine per day, unless the prescriber is an addiction specialist physician, or a consultation has been obtained from such a specialist recommending the higher dose. Dosage shall not exceed thirty-two milligrams of buprenorphine per day.
- (8) The physician shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4731-33-01 of the Administrative Code, who has the education and experience to provide substance use disorder counseling.
- (9) The physician may treat a patient using the administration of an extended-release, injectable, or implanted buprenorphine product.
  - (a) The physician shall strictly comply with any required risk evaluation and mitigation strategy program for the drug.
  - (b) The physician shall prescribe an extended-release buprenorphine product strictly in accordance with the United States food and drug administration's approved labeling for the drug's use.
  - (c) The physician shall document in the patient record the rationale for the use of the extended-release buprenorphine product.
  - (d) The physician who orders or prescribes an extended-release, injectable, or implanted buprenorphine product shall require it to be administered by an Ohio licensed health care professional acting in accordance within the scope of their professional license.

Replaces: 4731-33-03  
Effective: 10/31/2024  
Five Year Review (FYR) Dates: 10/31/2029

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 01/31/2015, 04/30/2019



## TO BE RESCINDED

4731-33-03

**Office-based treatment for opioid addiction.**

(A) A physician who provides OBOT shall comply with all of the following requirements:

- (1) Before initiating OBOT, the physician shall comply with section 3719.064 of the Revised Code.
- (2) Comply with all federal and state laws and regulations governing the prescribing of the medication; and
- (3) Complete at least eight hours of "Category 1" continuing medical education relating to substance abuse and addiction every two years. Courses completed in compliance with this requirement shall be accepted toward meeting the physician's "Category 1" continuing medical education requirement for biennial renewal of the physician's license.

(B) The physician who provides OBOT shall perform and document an assessment of the patient.

- (1) The assessment shall include all of the following:
  - (a) A comprehensive medical and psychiatric history;
  - (b) A brief mental status exam;
  - (c) Substance abuse history;
  - (d) Family history and psychosocial supports;
  - (e) Appropriate physical examination;
  - (f) Urine drug screen or oral fluid drug testing;
  - (g) Pregnancy test for women of childbearing age and ability;
  - (h) Review of the patient's prescription information in OARRS;
  - (i) Testing for human immunodeficiency virus;
  - (j) Testing for hepatitis B;
  - (k) Testing for hepatitis C; and

- (1) Consideration of screening for tuberculosis and sexually-transmitted diseases in patients with known risk factors.
  - (2) For other than the toxicology tests for drugs and alcohol, appropriate history, substance abuse history, and pregnancy test, the physician may satisfy the assessment requirements by reviewing records from a physical examination and laboratory testing of the patient that was conducted within a reasonable period of time prior to the visit.
  - (3) If any part of the assessment cannot be completed prior to the initiation of OBOT, the physician shall document the reasons in the medical record.
- (C) The physician who provides OBOT shall establish and document a treatment plan that includes all of the following:
- (1) The physician's rationale for selection of the specific drug to be used in the medication-assisted treatment;
  - (2) Patient education;
  - (3) The patient's written, informed consent;
  - (4) Random urine-drug screens;
  - (5) A signed treatment agreement that outlines the responsibilities of the patient and the physician; and
  - (6) A plan for psychosocial treatment, pursuant to paragraph (E) of this rule.
- (D) The physician shall provide OBOT in accordance with an acceptable treatment protocol for assessment, induction, stabilization, maintenance, and tapering. Acceptable protocols are any of the following:
- (1) SAMHSA treatment improvement protocol publications for medication assisted treatment available from the SAMHSA website at: <https://store.samhsa.gov>.
  - (2) "National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use," approved by the American society of addiction medicine in 2015, available from the website of the American society of addiction medicine at <https://www.asam.org/>.
- (E) Except if the physician providing OBOT is a board certified addictionologist, board certified addiction psychiatrist, or psychiatrist, the physician shall refer and work jointly with a qualified behavioral healthcare provider, community mental health

services provider, or community addiction services provider, as those terms are defined in rule 4731-33-01 of the Administrative Code, to determine the optimal type and intensity of psychosocial treatment for the patient and document the treatment plan in the patient record.

- (1) The treatment shall, at a minimum, include a psychosocial needs assessment, supportive counseling, links to existing family supports, and referral to community services.
- (2) The treatment shall include at least one of the following interventions, unless reasons for exception are documented in the patient record:
  - (a) Cognitive behavioral treatment;
  - (b) Community reinforcement approach;
  - (c) Contingency management/motivational incentives;
  - (d) Motivational interviewing; or
  - (e) Behavioral couples counseling.
- (3) The treatment plan shall include a structure for revision of the treatment plan if the patient does not adhere to the original plan.
- (4) When clinically appropriate and if the patient refuses treatment from a qualified behavioral healthcare provider, community mental health services provider, or community addiction services provider, as defined in rule 4731-33-01 of the Administrative Code, the physician shall ensure that the OBOT treatment plan requires the patient to participate in a twelve step program or appropriate self-help recovery program. If the patient is required to participate in a twelve step program or self-help recovery program, the physician shall require the patient to provide documentation of on-going participation in the program.
- (5) Additional requirements related to the provider of behavioral health services:
  - (a) If the physician providing OBOT is a board certified addictionologist, psychiatrist, or board certified psychiatrist, the physician may personally provide behavioral health services for addiction.
  - (b) If the physician refers the patient to a qualified behavioral healthcare provider, community addiction services provider, or community mental health services provider, the physician shall document the referral and the

physician's maintenance of meaningful interactions with the provider in the patient record.

(F) The physician who provides OBOT shall offer the patient a prescription for a naloxone kit.

- (1) The physician shall ensure that the patient receives instruction on the kit's use including, but not limited to, recognizing the signs and symptoms of overdose and calling 911 in an overdose situation.
- (2) The physician shall offer the patient a new prescription for naloxone upon expiration or use of the old kit.
- (3) The physician shall be exempt from this requirement if the patient refuses the prescription. If the patient refuses the prescription the physician shall provide the patient with information on where to obtain a kit without a prescription.

(G) In addition to paragraphs (A) to (F) of this rule, the physician who provides OBOT using buprenorphine products shall comply with all of the following requirements:

- (1) The provision shall be in compliance with the United States food and drug administration approved "Risk Evaluation and Mitigation Strategy" for buprenorphine products, which can be found on the United States food and drug administration website at the following address: <https://www.accessdata.fda.gov/scripts/cder/remis/index.cfm>. With the exception of those conditions listed in paragraph (G)(2) of this rule, a physician who treats the opioid use disorder with a buprenorphine product shall only prescribe buprenorphine/naloxone combination products for use in OBOT.
- (2) The physician shall prescribe buprenorphine without naloxone (buprenorphine mono-product) only in the following situations, and shall fully document the evidence for the decision to use buprenorphine mono-product in the medical record:
  - (a) When a patient is pregnant or breast-feeding;
  - (b) When converting a patient from buprenorphine mono-product to buprenorphine/naloxone combination product;
  - (c) In formulations other than tablet or film form for indications approved by the United States food and drug administration;

- (d) For withdrawal management when a buprenorphine/naloxone combination product is contraindicated, with the contraindication documented in the patient record; or
  - (e) When the patient has an allergy to or intolerance of a buprenorphine/naloxone combination product, after explaining to the patient the difference between an allergic reaction and symptoms of opioid withdrawal precipitated by buprenorphine or naloxone, and with documentation included in the patient record.
- (3) Due to a higher risk of fatal overdose when buprenorphine is prescribed with other opioids, benzodiazepines, sedative hypnotics, carisoprodol, or tramadol, the physician shall only co-prescribe these substances when it is medically necessary.
- (a) The physician shall verify the diagnosis for which the patient is receiving the other drug and coordinate care with the prescriber for the other drug, including whether it is possible to taper the drug to discontinuation. If the physician prescribing buprenorphine is the prescriber of the other drug, the physician shall taper the other drug to discontinuation, if it is safe to do so. The physician shall educate the patient about the serious risks of the combined use.
  - (b) The physician shall document progress with achieving the tapering plan.
- (4) During the induction phase the physician shall not prescribe a dosage that exceeds the recommendaton in the United States food and drug administration approved labeling, except for medically indicated circumstances as documented in the patient record. The physician shall see the patient at least once a week during this phase.
- (5) During the stabilization phase, when using any oral formulation of buprenorphine, the physician shall increase the daily dosage of buprenorphine in safe and effective increments to achieve the lowest dose that avoids intoxication, withdrawal, or significant drug craving.
- (a) During the first ninety days of treatment, the physician shall prescribe no more than a two-week supply of the buprenorphine product containing naloxone.
  - (b) Starting with the ninety-first day of treatment and until the completion of twelve months of treatment, the physician shall prescribe no more than a thirty-day supply of the buprenorphine product containing naloxone.

- (6) The physician shall take steps to reduce the chances of buprenorphine diversion by using the lowest effective dose, appropriate frequency of office visits, pill counts, and checks of OARRS. The physician shall require urine drug screens, serum medication levels, or oral fluid testing at least twice per quarter for the first year of treatment and at least once per quarter thereafter.
- (7) When using any oral formulation of buprenorphine, the physician shall document in the medical record the rationale for prescribed doses exceeding sixteen milligrams of buprenorphine per day. The physician shall not prescribe a dosage exceeding twenty-four milligrams of buprenorphine per day.
- (8) The physician shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4731-33-01 of the Administrative Code, who has the education and experience to provide substance abuse counseling.
- (9) The physician may treat a patient using the administration of an extended-release, injectable, or implanted buprenorphine product.
  - (a) The physician shall strictly comply with any required risk evaluation and mitigation strategy program for the drug.
  - (b) The physician shall prescribe an extended-release buprenorphine product strictly in accordance with the United States food and drug administration's approved labeling for the drug's use.
  - (c) The physician shall document in the patient record the rationale for the use of the extended-release buprenorphine product.
  - (d) The physician who orders or prescribes an extended-release, injectable, or implanted buprenorphine product shall require it to be administered by an Ohio licensed health care professional acting in accordance with the scope of the professional license.

Effective: 10/31/2024

Five Year Review (FYR) Dates: 7/25/2024

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 01/31/2015, 04/30/2019

4731-33-04**Medication-assisted treatment using naltrexone.**

(A) In addition to the requirements of paragraphs (A) to (E) of rule 4731-33-03 of the Administrative Code, the physician using naltrexone to treat opioid use disorder shall comply with the following requirements:

(1) Before initiating naltrexone, the physician shall take measures to ensure that the patient is opioid abstinent for an adequate period of time after completing opioid withdrawal to avoid precipitated withdrawal. The physician shall alert the patient of the risk of potentially lethal opioid overdose if they stop naltrexone and use opioids.

(2) The physician shall use oral naltrexone only for treatment of patients who are highly motivated.

(a) The dosage regime shall strictly comply with the food and drug administration approved labeling for naltrexone hydrochloride tablets.

(b) The patient shall be encouraged to have a support person administer and supervise the medication. Examples of a support person are a family member, close friend, or employer.

(c) The physician shall require urine drug screens, serum medication levels, or oral fluid drug testing at least every three months for the first year of treatment and at least every six months thereafter.

(d) The physician shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4731-33-01 of the Administrative Code, who has the education and experience to provide substance use disorder counseling.

(B) The physician may treat a patient with extended-release naltrexone for opioid or alcohol dependence or for co-occurring opioid and alcohol use disorders.

(1) The physician should consider treatment with extended-release naltrexone for patients who have difficulties with treatment adherence.

(2) The dosage shall strictly comply with the United States food and drug administration approved labeling for extended-release naltrexone.

(3) The physician shall determine the effectiveness of treatment with extended-release naltrexone by utilizing drug testing, serum medication levels, and oral fluid testing throughout the course of treatment.



- (4) The physician shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4731-33-01 of the Administrative Code, who has the education and experience to provide substance use disorder counseling.

Replaces: 4731-33-04  
Effective: 10/31/2024  
Five Year Review (FYR) Dates: 10/31/2029

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 04/30/2019

## TO BE RESCINDED

4731-33-04

**Medication-assisted treatment using naltrexone.**

- (A) In addition to the requirements of paragraphs (A) to (F) of rule 4731-33-03 of the Administrative Code, the physician using naltrexone to treat opioid use disorder shall comply with all of the following requirements:
- (1) Prior to treating a patient with naltrexone the physician shall inform the patient about the risk of opioid overdose if the patient ceases naltrexone and then uses opioids. The physician shall take measures to ensure that the patient is adequately detoxified from opioids and is no longer physically dependent prior to treatment with naltrexone.
  - (2) The physician shall use oral naltrexone only for treatment of patients who can be closely supervised and who are highly motivated.
    - (a) The dosage regime shall strictly comply with the food and drug administration approved labeling for naltrexone hydrochloride tablets.
    - (b) The patient shall be encouraged to have a support person administer and supervise the medication. Examples of a support person are a family member, close friend, or employer.
    - (c) The physician shall require urine drug screens, serum medication levels, or oral fluid drug testing at least every three months for the first year of treatment and at least every six months thereafter.
    - (d) The physician shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as defined in rule 4731-33-01 of the Administrative Code, who has the education and experience to provide substance abuse counseling.
- (B) The physician may treat a patient with extended-release naltrexone for opioid dependence or for co-occurring opioid and alcohol use disorders.
- (1) The physician should consider treatment with extended-release naltrexone for patients who have issues with treatment adherence.
  - (2) The injections dosage shall strictly comply with the United States food and drug administration approved labeling for extended-release naltrexone.
  - (3) The physician shall incorporate relapse prevention strategies into counseling or assure that they are addressed by a qualified behavioral healthcare provider, as

defined in rule 4731-33-01 of the Administrative Code, who has the education and experience to provide substance abuse counseling.

Effective: 10/31/2024

Five Year Review (FYR) Dates: 7/25/2024

CERTIFIED ELECTRONICALLY

---

Certification

10/10/2024

---

Date

Promulgated Under: 119.03  
Statutory Authority: 4731.05, 4731.056  
Rule Amplifies: 4731.056, 4731.83  
Prior Effective Dates: 04/30/2019